Search

Your search keyword '"Kleykamp, Bethea A."' showing total 166 results
Start Over Author "Kleykamp, Bethea A."
166 results on '"Kleykamp, Bethea A."'

4. Cannabis Perceptions and Patterns of Use Among Older Adult Cancer Survivors.

Author

Fahey, Margaret C., Walters, Kyle J., Benitez, Andreana M., Tomko, Rachel L., Kleykamp, Bethea A., and McClure, Erin A.

Subjects
MEDICAL marijuana, CROSS-sectional method, CANCER treatment, RESEARCH funding, INSOMNIA, SMOKING, CANCER patients, DESCRIPTIVE statistics, PAIN, SPECIALTY hospitals, THERAPEUTICS, OLD age
Abstract

Objectives: To descriptively assess cannabis perceptions and patterns of use among older adult cancer survivors in a state without a legal cannabis marketplace. Methods: This study used weighted prevalence estimates to cross-sectionally describe cannabis perceptions and patterns of use among older (65+) adults (N = 524) in a National Cancer Institute-designated center in a state without legal cannabis access. Results: Half (46 %) had ever used cannabis (18% following diagnosis and 10 % currently). Only 8% had discussed cannabis with their provider. For those using post-diagnosis, the most common reason was for pain (44%), followed by insomnia (43%), with smoking being the most common (40%) mode of use. Few (<3%) reported that cannabis had worsened any of their symptoms. Discussion: Even within a state without a legal cannabis marketplace, older cancer survivors might commonly use cannabis to alleviate health concerns but unlikely to discuss this with their providers. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

6. Basic Science and Public Policy: Informed Regulation for Nicotine and Tobacco Products

Author

Fowler, Christie D, Gipson, Cassandra D, Kleykamp, Bethea A, Rupprecht, Laura E, Harrell, Paul T, Rees, Vaughan W, Gould, Thomas J, Oliver, Jason, Bagdas, Deniz, Damaj, M Imad, Schmidt, Heath D, Duncan, Alexander, De Biasi, Mariella, and Nicotine and Tobacco, the Basic Science Network of the Society for Research on

Subjects
Epidemiology, Public Health, Health Sciences, Prevention, 8.3 Policy, ethics, and research governance, Good Health and Well Being, Biomedical Research, Humans, Nicotine, Public Policy, Tobacco Products, Tobacco Use Disorder, Basic Science Network (BSN) of the Society for Research on Nicotine and Tobacco, Clinical Sciences, Public Health and Health Services, Marketing, Public health
Abstract

IntroductionScientific discoveries over the past few decades have provided significant insight into the abuse liability and negative health consequences associated with tobacco and nicotine-containing products. While many of these advances have led to the development of policies and laws that regulate access to and formulations of these products, further research is critical to guide future regulatory efforts, especially as novel nicotine-containing products are introduced and selectively marketed to vulnerable populations.DiscussionIn this narrative review, we provide an overview of the scientific findings that have impacted regulatory policy and discuss considerations for further translation of science into policy decisions. We propose that open, bidirectional communication between scientists and policy makers is essential to develop transformative preventive- and intervention-focused policies and programs to reduce appeal, abuse liability, and toxicity of the products.ConclusionsThrough these types of interactions, collaborative efforts to inform and modify policy have the potential to significantly decrease the use of tobacco and alternative nicotine products and thus enhance health outcomes for individuals.ImplicationsThis work addresses current topics in the nicotine and tobacco research field to emphasize the importance of basic science research and provide examples of how it can be utilized to inform public policy. In addition to relaying current thoughts on the topic from experts in the field, the article encourages continued efforts and communication between basic scientists and policy officials.

Published
2018

8. Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement

Author

Hohenschurz-Schmidt, David, primary, Cherkin, Dan, additional, Rice, Andrew S.C., additional, Dworkin, Robert H., additional, Turk, Dennis C., additional, McDermott, Michael P., additional, Bair, Matthew J., additional, DeBar, Lynn L., additional, Edwards, Robert R., additional, Evans, Scott R., additional, Farrar, John T., additional, Kerns, Robert D., additional, Rowbotham, Michael C., additional, Wasan, Ajay D., additional, Cowan, Penney, additional, Ferguson, McKenzie, additional, Freeman, Roy, additional, Gewandter, Jennifer S., additional, Gilron, Ian, additional, Grol-Prokopczyk, Hanna, additional, Iyengar, Smriti, additional, Kamp, Cornelia, additional, Karp, Barbara I., additional, Kleykamp, Bethea A., additional, Loeser, John D., additional, Mackey, Sean, additional, Malamut, Richard, additional, McNicol, Ewan, additional, Patel, Kushang V., additional, Schmader, Kenneth, additional, Simon, Lee, additional, Steiner, Deborah J., additional, Veasley, Christin, additional, and Vollert, Jan, additional

Published
2024
Full Text
View/download PDF

9. Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations

Author

Kleykamp, Bethea A., Dworkin, Robert H., Turk, Dennis C., Bhagwagar, Zubin, Cowan, Penney, Eccleston, Christopher, Ellenberg, Susan S., Evans, Scott R., Farrar, John T., Freeman, Roy L., Garrison, Louis P., Gewandter, Jennifer S., Goli, Veeraindar, Iyengar, Smriti, Jadad, Alejandro R., Jensen, Mark P., Junor, Roderick, Katz, Nathaniel P., Kesslak, J. Patrick, Kopecky, Ernest A., Lissin, Dmitri, Markman, John D., McDermott, Michael P., Mease, Philip J., OʼConnor, Alec B., Patel, Kushang V., Raja, Srinivasa N., Rowbotham, Michael C., Sampaio, Cristina, Singh, Jasvinder A., Steigerwald, Ilona, Strand, Vibeke, Tive, Leslie A., Tobias, Jeffrey, Wasan, Ajay D., and Wilson, Hilary D.

Published
2022
Full Text
View/download PDF

13. Patient engagement in designing, conducting, and disseminating clinical pain research: IMMPACT recommended considerations

Author

Haroutounian, Simon, primary, Holzer, Katherine J., additional, Kerns, Robert D., additional, Veasley, Christin, additional, Dworkin, Robert H., additional, Turk, Dennis C., additional, Carman, Kristin L., additional, Chambers, Christine T., additional, Cowan, Penney, additional, Edwards, Robert R., additional, Eisenach, James C., additional, Farrar, John T., additional, Ferguson, McKenzie, additional, Forsythe, Laura P., additional, Freeman, Roy, additional, Gewandter, Jennifer S., additional, Gilron, Ian, additional, Goertz, Christine, additional, Grol-Prokopczyk, Hanna, additional, Iyengar, Smriti, additional, Jordan, Isabel, additional, Kamp, Cornelia, additional, Kleykamp, Bethea A., additional, Knowles, Rachel L., additional, Langford, Dale J., additional, Mackey, Sean, additional, Malamut, Richard, additional, Markman, John, additional, Martin, Kathryn R., additional, McNicol, Ewan, additional, Patel, Kushang V., additional, Rice, Andrew S.C., additional, Rowbotham, Michael, additional, Sandbrink, Friedhelm, additional, Simon, Lee S., additional, Steiner, Deborah J., additional, and Vollert, Jan, additional

Published
2023
Full Text
View/download PDF

15. Basic Science and Public Policy : Informed Regulation for Nicotine and Tobacco Products

Author

Basic Science Network (BSN) of the Society for Research on Nicotine and Tobacco (SRNT), Fowler, Christie D., Gipson, Cassandra D., Kleykamp, Bethea A., Rupprecht, Laura E., Harrell, Paul T., Rees, Vaughan W., Gould, Thomas J., Oliver, Jason, Bagdas, Deniz, Damaj, M. Imad, Schmidt, Heath D., Duncan, Alexander, and De Biasi, Mariella

Published
2018

21. Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement

Author

Hohenschurz-Schmidt, David J., primary, Cherkin, Dan, additional, Rice, Andrew S.C., additional, Dworkin, Robert H., additional, Turk, Dennis C., additional, McDermott, Michael P., additional, Bair, Matthew J., additional, DeBar, Lynn L., additional, Edwards, Robert R., additional, Farrar, John T., additional, Kerns, Robert D., additional, Markman, John D., additional, Rowbotham, Michael C., additional, Sherman, Karen J., additional, Wasan, Ajay D., additional, Cowan, Penney, additional, Desjardins, Paul, additional, Ferguson, McKenzie, additional, Freeman, Roy, additional, Gewandter, Jennifer S., additional, Gilron, Ian, additional, Grol-Prokopczyk, Hanna, additional, Hertz, Sharon H., additional, Iyengar, Smriti, additional, Kamp, Cornelia, additional, Karp, Barbara I., additional, Kleykamp, Bethea A., additional, Loeser, John D., additional, Mackey, Sean, additional, Malamut, Richard, additional, McNicol, Ewan, additional, Patel, Kushang V., additional, Sandbrink, Friedhelm, additional, Schmader, Kenneth, additional, Simon, Lee, additional, Steiner, Deborah J., additional, Veasley, Christin, additional, and Vollert, Jan, additional

Published
2023
Full Text
View/download PDF

22. Real-world data and evidence in pain research: a qualitative systematic review of methods in current practice

Author

Vollert, Jan, primary, Kleykamp, Bethea A., additional, Farrar, John T., additional, Gilron, Ian, additional, Hohenschurz-Schmidt, David, additional, Kerns, Robert D., additional, Mackey, Sean, additional, Markman, John D., additional, McDermott, Michael P., additional, Rice, Andrew S.C., additional, Turk, Dennis C., additional, Wasan, Ajay D., additional, and Dworkin, Robert H., additional

Published
2023
Full Text
View/download PDF

24. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder

Author

Kiluk, Brian D., primary, Kleykamp, Bethea A., additional, Comer, Sandra D., additional, Griffiths, Roland R., additional, Huhn, Andrew S., additional, Johnson, Matthew W., additional, Kampman, Kyle M., additional, Pravetoni, Marco, additional, Preston, Kenzie L., additional, Vandrey, Ryan, additional, Bergeria, Cecilia L., additional, Bogenschutz, Michael P., additional, Brown, Randall T., additional, Dunn, Kelly E., additional, Dworkin, Robert H., additional, Finan, Patrick H., additional, Hendricks, Peter S., additional, Houtsmuller, Elisabeth J., additional, Kosten, Thomas R., additional, Lee, Dustin C., additional, Levin, Frances R., additional, McRae-Clark, Aimee, additional, Raison, Charles L., additional, Rasmussen, Kurt, additional, Turk, Dennis C., additional, Weiss, Roger D., additional, and Strain, Eric C., additional

Published
2023
Full Text
View/download PDF

25. ASAMClinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids.

Author

Weimer, Melissa B., Herring, Andrew A., Kawasaki, Sarah S., Meyer, Marjorie, Kleykamp, Bethea A., and Ramsey, Kelly S.

Abstract

Treatment of opioid use disorder (OUD) with buprenorphine has evolved considerably in the last decade as the scale of the OUD epidemic has increased along with the emergence of high-potency synthetic opioids (HPSOs) and stimulants in the drug supply. These changes have outpaced the development of prospective research, so a clinical consideration document based on expert consensus is needed to address pressing clinical questions. This clinical considerations document is based on a narrative literature review and expert consensus and will specifically address considerations for changes to the clinical practice of treatment of OUD with buprenorphine for individuals using HPSO. An expert panel developed 6 key questions addressing buprenorphine initiation, stabilization, and long-term treatment for individuals with OUD exposed to HPSO in various treatment settings. Broadly, the clinical considerations suggest that individualized strategies for buprenorphine initiation may be needed. The experience of opioid withdrawal negatively impacts the success of buprenorphine treatment, and attention to its management before and during buprenorphine initiation should be proactively addressed. Buprenorphine dose and dosing frequency should be individualized based on patients' treatment needs, the possibility of novel components in the drug supply should be considered during OUD treatment, and all forms of opioid agonist treatment should be offered and considered for patients. Together, these clinical considerations attempt to be responsive to the challenges and opportunities experienced by frontline clinicians using buprenorphine for the treatment of OUD in patients using HPSOs and highlight areas where prospective research is urgently needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Design and reporting characteristics of clinical trials investigating sedation practices in the paediatric intensive care unit: a scoping review by SCEPTER (Sedation Consortium on Endpoints and Procedures for Treatment, Education and Research)

Author

Lee, Jennifer Jooyoung, primary, Price, Jerri C, additional, Gewandter, Jennifer, additional, Kleykamp, Bethea A, additional, Biagas, Katherine V, additional, Naim, Maryam Y, additional, Ward, Denham, additional, Dworkin, Robert H, additional, and Sun, Lena S, additional

Published
2021
Full Text
View/download PDF

31. Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations

Author

Kleykamp, Bethea A., primary, Dworkin, Robert H., additional, Turk, Dennis C., additional, Bhagwagar, Zubin, additional, Cowan, Penney, additional, Eccleston, Christopher, additional, Ellenberg, Susan S., additional, Evans, Scott R., additional, Farrar, John T., additional, Freeman, Roy L., additional, Garrison, Louis P., additional, Gewandter, Jennifer S., additional, Goli, Veeraindar, additional, Iyengar, Smriti, additional, Jadad, Alejandro R., additional, Jensen, Mark P., additional, Junor, Roderick, additional, Katz, Nathaniel P., additional, Kesslak, J. Patrick, additional, Kopecky, Ernest A., additional, Lissin, Dmitri, additional, Markman, John D., additional, McDermott, Michael P., additional, Mease, Philip J., additional, O'Connor, Alec B., additional, Patel, Kushang V., additional, Raja, Srinivasa N., additional, Rowbotham, Michael C., additional, Sampaio, Cristina, additional, Singh, Jasvinder A., additional, Steigerwald, Ilona, additional, Strand, Vibeke, additional, Tive, Leslie A., additional, Tobias, Jeffrey, additional, Wasan, Ajay D., additional, and Wilson, Hilary D., additional

Published
2021
Full Text
View/download PDF

34. Pragmatic trials of pain therapies: a systematic review of methods

Author

Hohenschurz-Schmidt, David, primary, Kleykamp, Bethea A., additional, Draper-Rodi, Jerry, additional, Vollert, Jan, additional, Chan, Jessica, additional, Ferguson, McKenzie, additional, McNicol, Ewan, additional, Phalip, Jules, additional, Evans, Scott R., additional, Turk, Dennis C., additional, Dworkin, Robert H., additional, and Rice, Andrew S.C., additional

Published
2021
Full Text
View/download PDF

44. Pragmatic trials of pain therapies: a systematic review of methods.

Author

Hohenschurz-Schmidt, David, Kleykamp, Bethea A., Draper-Rodi, Jerry, Vollert, Jan, Chan, Jessica, Ferguson, McKenzie, McNicol, Ewan, Phalip, Jules, Evans, Scott R., Turk, Dennis C., Dworkin, Robert H., and Rice, Andrew S.C.

Subjects
*PAIN management, *CLINICAL trials, *RANDOMIZED controlled trials, *PATIENT selection, *PATIENT compliance, *EXPERIMENTAL design, *PAIN, *META-analysis, *SYSTEMATIC reviews
Abstract

Abstract: Pragmatic randomised clinical trials aim to directly inform clinical or health policy decision making. Here, we systematically review methods and design of pragmatic trials of pain therapies to examine methods, identify common challenges, and areas for improvement. Seven databases were searched for pragmatic randomised controlled clinical trials that assessed pain treatment in a clinical population of adults reporting pain. All screening steps and data extractions were performed twice. Data were synthesised descriptively, and correlation analyses between prespecified trial features and PRECIS-2 (PRagmatic-Explanatory Continuum Indicator Summary 2) ratings and attrition were performed. Protocol registration: PROSPERO-ID CRD42020178954. Of 57 included trials, only 21% assessed pharmacological interventions, the remainder physical, surgical, psychological, or self-management pain therapies. Three-quarters of the trials were comparative effectiveness designs, often conducted in multiple centres (median: 5; Q1/3: 1, 9.25) and with a median sample size of 234 patients at randomization (Q1/3: 135.5; 363.5). Although most trials recruited patients with chronic pain, reporting of pain duration was poor and not well described. Reporting was comprehensive for most general items, while often deficient for specific pragmatic aspects. Average ratings for pragmatism were highest for treatment adherence flexibility and clinical relevance of outcome measures. They were lowest for patient recruitment methods and extent of follow-up measurements and appointments. Current practice in pragmatic trials of pain treatments can be improved in areas such as patient recruitment and reporting of methods, analysis, and interpretation of data. These improvements will facilitate translatability to other real-world settings-the purpose of pragmatic trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Craving and opioid use disorder: A scoping review

Author

Kleykamp, Bethea A., primary, De Santis, Marta, additional, Dworkin, Robert H., additional, Huhn, Andrew S., additional, Kampman, Kyle M., additional, Montoya, Ivan D., additional, Preston, Kenzie L., additional, Ramey, Tanya, additional, Smith, Shannon M., additional, Turk, Dennis C., additional, Walsh, Robert, additional, Weiss, Roger D., additional, and Strain, Eric C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results